S&P 500   3,346.94 (-0.07%)
DOW   27,317.01 (-0.26%)
QQQ   273.79 (-0.31%)
AAPL   450.75 (-1.07%)
MSFT   214.52 (-0.85%)
FB   274.45 (+3.46%)
GOOGL   1,511.50 (+0.44%)
AMZN   3,216.01 (-0.28%)
NVDA   454.34 (+0.20%)
CGC   17.11 (-2.34%)
BABA   255.36 (-3.88%)
TSLA   1,472.99 (-1.11%)
MU   48.73 (+0.06%)
GE   6.29 (-0.63%)
AMD   85.72 (-1.14%)
T   29.65 (-0.64%)
F   6.82 (-1.59%)
ACB   10.19 (-1.16%)
GILD   69.01 (+0.29%)
NFLX   501.02 (-1.58%)
DIS   130.75 (-0.05%)
BAC   25.41 (-0.24%)
BA   171.41 (-0.46%)
S&P 500   3,346.94 (-0.07%)
DOW   27,317.01 (-0.26%)
QQQ   273.79 (-0.31%)
AAPL   450.75 (-1.07%)
MSFT   214.52 (-0.85%)
FB   274.45 (+3.46%)
GOOGL   1,511.50 (+0.44%)
AMZN   3,216.01 (-0.28%)
NVDA   454.34 (+0.20%)
CGC   17.11 (-2.34%)
BABA   255.36 (-3.88%)
TSLA   1,472.99 (-1.11%)
MU   48.73 (+0.06%)
GE   6.29 (-0.63%)
AMD   85.72 (-1.14%)
T   29.65 (-0.64%)
F   6.82 (-1.59%)
ACB   10.19 (-1.16%)
GILD   69.01 (+0.29%)
NFLX   501.02 (-1.58%)
DIS   130.75 (-0.05%)
BAC   25.41 (-0.24%)
BA   171.41 (-0.46%)
S&P 500   3,346.94 (-0.07%)
DOW   27,317.01 (-0.26%)
QQQ   273.79 (-0.31%)
AAPL   450.75 (-1.07%)
MSFT   214.52 (-0.85%)
FB   274.45 (+3.46%)
GOOGL   1,511.50 (+0.44%)
AMZN   3,216.01 (-0.28%)
NVDA   454.34 (+0.20%)
CGC   17.11 (-2.34%)
BABA   255.36 (-3.88%)
TSLA   1,472.99 (-1.11%)
MU   48.73 (+0.06%)
GE   6.29 (-0.63%)
AMD   85.72 (-1.14%)
T   29.65 (-0.64%)
F   6.82 (-1.59%)
ACB   10.19 (-1.16%)
GILD   69.01 (+0.29%)
NFLX   501.02 (-1.58%)
DIS   130.75 (-0.05%)
BAC   25.41 (-0.24%)
BA   171.41 (-0.46%)
S&P 500   3,346.94 (-0.07%)
DOW   27,317.01 (-0.26%)
QQQ   273.79 (-0.31%)
AAPL   450.75 (-1.07%)
MSFT   214.52 (-0.85%)
FB   274.45 (+3.46%)
GOOGL   1,511.50 (+0.44%)
AMZN   3,216.01 (-0.28%)
NVDA   454.34 (+0.20%)
CGC   17.11 (-2.34%)
BABA   255.36 (-3.88%)
TSLA   1,472.99 (-1.11%)
MU   48.73 (+0.06%)
GE   6.29 (-0.63%)
AMD   85.72 (-1.14%)
T   29.65 (-0.64%)
F   6.82 (-1.59%)
ACB   10.19 (-1.16%)
GILD   69.01 (+0.29%)
NFLX   501.02 (-1.58%)
DIS   130.75 (-0.05%)
BAC   25.41 (-0.24%)
BA   171.41 (-0.46%)
Log in

NASDAQ:ODTOdonate Therapeutics Stock Price, Forecast & News

$37.10
-0.15 (-0.40 %)
(As of 08/7/2020 11:38 AM ET)
Add
Compare
Today's Range
$36.82
Now: $37.10
$37.23
50-Day Range
$35.40
MA: $39.12
$42.74
52-Week Range
$18.07
Now: $37.10
$46.50
Volume298 shs
Average Volume89,823 shs
Market Capitalization$1.19 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.02
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Read More
Odonate Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.92 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ODT
CUSIPN/A
Phone858-731-8180

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.29 per share

Profitability

Net Income$-111,820,000.00

Miscellaneous

Employees117
Market Cap$1.19 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$37.10
-0.15 (-0.40 %)
(As of 08/7/2020 11:38 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ODT News and Ratings via Email

Sign-up to receive the latest news and ratings for ODT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions

How has Odonate Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ODT shares have increased by 43.0% and is now trading at $37.07.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Odonate Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell."
View analyst ratings for Odonate Therapeutics
.

When is Odonate Therapeutics' next earnings date?

Odonate Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Odonate Therapeutics
.

How were Odonate Therapeutics' earnings last quarter?

Odonate Therapeutics Inc (NASDAQ:ODT) released its earnings results on Thursday, July, 30th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.98) by $0.11.
View Odonate Therapeutics' earnings history
.

What price target have analysts set for ODT?

1 Wall Street analysts have issued twelve-month price targets for Odonate Therapeutics' stock. Their forecasts range from $26.00 to $26.00. On average, they anticipate Odonate Therapeutics' share price to reach $26.00 in the next twelve months. This suggests that the stock has a possible downside of 29.9%.
View analysts' price targets for Odonate Therapeutics
.

Has Odonate Therapeutics been receiving favorable news coverage?

Headlines about ODT stock have trended positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Odonate Therapeutics earned a daily sentiment score of 2.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Odonate Therapeutics
.

Are investors shorting Odonate Therapeutics?

Odonate Therapeutics saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 849,400 shares, an increase of 11.1% from the July 15th total of 764,300 shares. Based on an average daily trading volume, of 78,000 shares, the short-interest ratio is currently 10.9 days. Currently, 2.9% of the shares of the stock are short sold.
View Odonate Therapeutics' Current Options Chain
.

Who are some of Odonate Therapeutics' key competitors?

What other stocks do shareholders of Odonate Therapeutics own?

Who are Odonate Therapeutics' key executives?

Odonate Therapeutics' management team includes the following people:
  • Mr. Kevin C. Tang, Chairman & CEO (Age 52)
  • Mr. John G. Lemkey, Chief Operating Officer (Age 38)
  • Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 65)
  • Mr. Michael S. Hearne, CFO & Principal Accounting Officer (Age 57)
  • Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 43)

When did Odonate Therapeutics IPO?

(ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.

What is Odonate Therapeutics' stock symbol?

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

Who are Odonate Therapeutics' major shareholders?

Odonate Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.16%), Swiss National Bank (0.09%), Bessemer Group Inc. (0.06%), Strs Ohio (0.04%), Chartwell Investment Partners LLC (0.04%) and New York State Common Retirement Fund (0.04%). Company insiders that own Odonate Therapeutics stock include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang.
View institutional ownership trends for Odonate Therapeutics
.

Which major investors are selling Odonate Therapeutics stock?

ODT stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Chartwell Investment Partners LLC, Virtus ETF Advisers LLC, and UBS Group AG.
View insider buying and selling activity for Odonate Therapeutics
.

Which major investors are buying Odonate Therapeutics stock?

ODT stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Bessemer Group Inc., SG Americas Securities LLC, Russell Investments Group Ltd., New York State Common Retirement Fund, and Swiss National Bank. Company insiders that have bought Odonate Therapeutics stock in the last two years include Boxer Capital, Llc, Jeff L Vacirca, and Kevin C Tang.
View insider buying and selling activity for Odonate Therapeutics
.

How do I buy shares of Odonate Therapeutics?

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Odonate Therapeutics' stock price today?

One share of ODT stock can currently be purchased for approximately $37.07.

How big of a company is Odonate Therapeutics?

Odonate Therapeutics has a market capitalization of $1.19 billion. The company earns $-111,820,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe.

What is Odonate Therapeutics' official website?

The official website for Odonate Therapeutics is www.odonate.com.

How can I contact Odonate Therapeutics?

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.